Green Cross Corporation
Green Cross Corporation (GC Holdings) is a South Korean publicly traded healthcare holding company operating 40 affiliates that develop, manufacture, and commercialize plasma derivatives, vaccines (BARYCELA, MAV/06 strain), rare disease therapies, cell and gene therapies, diagnostics, and consumer health products across Korea, the US, China, Japan, and Brazil.
- Company typePublic
- Founded1969
- HeadquartersGiheung, South Korea
- Headcount1,001–5,000
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Green Cross Corporation does
Green Cross Corporation (GC Holdings / GC; ticker 006280.KS) is a South Korea-based publicly traded holding company that operates a 40-affiliate global total healthcare group spanning biopharmaceuticals, plasma derivatives, vaccines, rare disease treatments, cell and gene therapies, in-vitro diagnostics, consumer health, and digital healthcare. Founded in 1967 and headquartered in Yongin-si (Giheung-gu), the group's core operating entity GC Biopharma manufactures and markets plasma-derived products including the IVIG brand Alyglo (US-launched 2024), the world's first antibiotic-free varicella vaccine BARYCELA using the proprietary MAV/06 strain (WHO PQ-certified 2023), and rare disease therapies such as Hunterase (Hunter syndrome) and Greenegene F (hemophilia A). The technology stack spans an mRNA-LNP drug delivery platform, AI-based RNA design through Mogam Institute, bispecific ADCs (EGFR x cMET), and an in-vivo CAR-T program developed with Appclone, supported by Asia's largest cell therapy manufacturing facility (GC Cell Center) and Asia's #1 EMR system (GC MediAI, serving 25,000+ Korean clinics).
Revenue is generated across multiple streams: enterprise field sales to hospitals, clinics, blood centers, and government health agencies; international public procurement (WHO/UNICEF) for WHO PQ-certified vaccines; co-development licensing arrangements (Hanmi Pharmaceutical for Fabry disease GC1134A, Canvera for ADC GC1148A, Appclone for in-vivo CAR-T, ST Pharm for AI-RNA); CDMO and central lab services through GC Cell and GCCL; and direct-to-consumer sales of health functional foods and placenta-extract products via GC Wellbeing and Ernisty online/retail channels. Distribution leverages wholly-owned regional subsidiaries in the US (Fort Lee, San Antonio, San Diego, Newark, Seattle, Irvine), China (Huainan manufacturing), Japan (Tokyo), and Brazil (São Paulo), giving GC regulatory-anchored access to North America, Latin America, and Asia-Pacific markets.
Green Cross Corporation firmographics
Firmographics- Name
- Green Cross Corporation
- Legal name
- 주식회사 녹십자홀딩스
- Website
- https://gccorp.com
- Company type
- Public
- Founded year
- 1969
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Green Cross Corporation (GC Holdings) is a South Korean publicly traded healthcare holding company operating 40 affiliates that develop, manufacture, and commercialize plasma derivatives, vaccines (BARYCELA, MAV/06 strain), rare disease therapies, cell and gene therapies, diagnostics, and consumer health products across Korea, the US, China, Japan, and Brazil.
- Ownership category
- akta.pro rank
Green Cross Corporation industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Medical Laboratories (621511), Food (Health) Supplement Retailers (456191)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Cell Therapy CDMO (HLAGABAD)
- akta.pro secondary industry
- Health & Wellness (Vitamins, Supplements, OTC) DTC (CRAFACAC)
Keywords
Where Green Cross Corporation is headquartered
LocationHeadquarters
- HQ city
- Giheung
- HQ country
- South Korea
- HQ region
- Asia
Offices18 records
Markets served
Green Cross Corporation business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Plasma Derivatives (Blood Products): GC Biopharma's core revenue driver, including intravenous immunoglobulin (IVIG) products such as Alyglo (ALYGLO, GC5131A), albumin, coagulation factors, and other plasma-derived therapeutics. Manufactured at GMP-certified Ochang plant.
- Vaccines: Sales of varicella vaccines (BARYCELA, using MAV/06 strain), quadrivalent influenza vaccine (GCFLU Quadrivalent), COVID-19 vaccine, and other pediatric/adult vaccines. Includes WHO PQ-certified products for global public procurement markets.
- Rare Disease Treatments: High-value specialty pharmaceuticals including Hunter syndrome treatment (Hunterase/Idursulfase), Fabry disease treatment (GC1134A/HM15421, co-developed with Hanmi Pharmaceutical), and other ultra-rare disease therapeutics.
- Cell and Gene Therapies: Revenue from CAR-NK cell therapy pipeline (via Artiva Biotherapeutics), cell therapy CDMO services from GC Cell's Asia's largest cell therapy manufacturing facility (Cell Center), and future in vivo CAR-T products.
- In Vitro Diagnostics and Medical Devices: GC MS, GC Medis, GCCL, and GC Genome generate revenue from diagnostic reagents, point-of-care testing devices (blood glucose, HbA1c, lactic acid biosensors), clinical trial lab services, and genomic testing services.
- Consumer Health Products: Health functional foods, nutritional supplements, placenta extracts, and wellness products sold through GC Wellbeing and Ernisty to individual consumers via online and retail channels.
Go-to-market motion2 records
Distribution channels7 records
Marketing channels6 records
Green Cross Corporation product offering
Product offeringCore offering
Green Cross Corporation (GC Holdings) is a Korean healthcare conglomerate operating through 40 affiliates (25 domestic, 15 overseas) that develops, manufactures, and commercializes plasma derivatives (IVIG, albumin), vaccines (varicella, influenza, hemorrhagic fever), rare disease treatments (Hunter syndrome, hemophilia, Fabry disease), and innovative therapeutics including mRNA-LNP vaccines, bispecific ADCs, and in vivo CAR-T cell therapies. The group also provides in vitro diagnostics, clinical trial lab services, consumer health functional foods, digital healthcare platforms, and cell therapy CDMO services through dedicated subsidiaries.
Product overview
GC (Green Cross Corporation / 녹십자홀딩스) is a biotech-based global total healthcare group encompassing disease prevention, diagnosis, treatment, medical devices, and wellness services across 40 affiliates. The portfolio includes: (1) GC녹십자 (GC Biopharma) as the core pharmaceutical entity developing plasma derivatives, vaccines (BARYCELA, flu, hemorrhagic fever), rare disease treatments (Hunterase, Greenegene F), and innovative pipeline (mRNA vaccines, ADC, in vivo CAR-T); (2) GC Cell for cell/gene therapy with Asia's largest manufacturing facility; (3) Diagnostic companies (GC MS, GCCL, GC Genome, GC Medis, Genes Laboratories) providing IVD reagents, clinical lab services, and genomics; (4) Consumer health brands (GC Wellbeing, GC Care) for health functional foods and digital health; (5) Healthcare services (GC i-MED, GC Labs, Dr.GC clinic); (6) Research foundation (MOGAM Institute) pioneering AI-driven drug discovery; (7) Engineering (GCEM) for GMP facilities; (8) International subsidiaries in US, China, Japan, Brazil, and biotech investments globally.
Differentiator
Problem solved
Functional benefit
Brands
- THE FAB FIVE: GC녹십자의 5대 핵심 R&D 파이프라인 자산 (20% SCIG, mCOVID 백신, EBV 서브유닛 백신, 파브리병 치료제, EGFR X cMET ADC)
- MAV/06
- BARYCELA
- ALYGLO
- ALYGLO (알리글로)
- 헌터라제
- 그린진
- 인비보 카티
- INIBO (이니보)
- Broccoli365
Quantifiable outcome
- MAV/06 varicella vaccine: 99-100% seroconversion rate in clinical trials; adverse event incidence of 0.41-0.57 cases per 100,000 doses (lower than major global vaccines)
- +4 more outcomes
Companies that use Green Cross Corporation
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles4 records
Green Cross Corporation technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature5 records
Green Cross Corporation partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and major.
- ST Pharm (에스티팜)coreMogam Institute for Biomedical Research and ST Pharm signed a joint R&D agreement for AI-based RNA design and optimization technology. Mogam contributes its AI platform (generative AI, bio-foundation models) for RNA structure design; ST Pharm contributes its RNA drug development and manufacturing technology. The goal is to accelerate next-generation RNA therapeutic development by combining AI with RNA platform capabilities.
- Appclone (앱클론)coreGC Biopharma and Appclone signed a strategic MOU for joint development of next-generation in vivo CAR-T (Invivo CAR-T) therapy. GC contributes its mRNA-LNP platform and GMP manufacturing capabilities; Appclone contributes its proprietary CAR technology, T-cell-specific antibody assets, and extensive CAR clinical experience. The partnership aims to create an off-the-shelf CAR-T product that can be administered like a vaccine, enabling same-day treatment without patient cell extraction.
- Medicover Integrated Clinical Services (MICS)majorGCCL and MICS (part of Medicover, international healthcare and diagnostic services company) signed an MOU for multinational clinical trial services collaboration covering Europe, US, and Asia-Pacific regions. Key collaboration areas include clinical trial operations and sample analysis across regions; project management support; joint marketing and client development; and service competitiveness enhancement through test item alignment and improved analytical efficiency.
- OPIS (Optimus Integrated Services)majorGCCL and OPIS signed an MOU on the sidelines of the 44th Annual J.P. Morgan Healthcare Conference 2026 to expand collaboration and strengthen global clinical trial market position. The partnership combines OPIS's Europe-focused global CRO network with GCCL's clinical trial sample analysis expertise to deliver integrated and efficient clinical trial solutions spanning planning, sample analysis, and data management across Europe and Asia.
- Hanmi Pharmaceutical (한미약품)majorGC Biopharma and Hanmi Pharmaceutical are co-developing Fabry disease treatment (GC1134A/HM15421). The drug is undergoing Phase 1/2 clinical trials in the US, Korea, and Argentina. Hanmi contributes co-development funding and regional clinical trial support in Korea.
- Canvera Therapeutics (카나프테라퓨틱스)majorGC Biopharma and Canvera Therapeutics are co-developing EGFR x cMET bispecific ADC (GC1148A) for solid tumor treatment. Canvera contributes its bispecific ADC platform technology; GC contributes its antibody development and GMP manufacturing capabilities. The partnership aims to advance the dual-targeting ADC into preclinical and clinical development.
- Artiva BiotherapeuticscoreGC Cell (via its US subsidiary) established Artiva Biotherapeutics in San Diego in 2019 for NK cell therapy development and commercialization in the US market. Artiva operates as an NRDO (No Research Development Only) company, licensing GC Cell's CAR technology and NK cell therapy pipeline assets. GC Cell retains technology leadership while Artiva focuses on US clinical development and commercialization.
- Infectious Disease Research Institute (IDRI)coreCurevo (GC Group subsidiary, Seattle) collaborates with IDRI for vaccine research and development. IDRI is a globally recognized vaccine research institution; the partnership provides Curevo with specialized vaccine research expertise supporting its next-generation shingles vaccine clinical development program.
Scale indicators8 records
Recent moves8 records
Expansion highlights6 records
Green Cross Corporation competitors and assessment
Company assessmentDirect peers
- Iovance Biotherapeutics: US-based cell therapy company developing autologous tumor-infiltrating lymphocyte (TIL) therapies for solid tumors. Comparable to GC Cell as a pure-play cell therapy developer competing in the same oncology cell therapy market with GMP manufacturing scale.
- Samsung Biologics: Korean biopharma CDMO providing contract manufacturing services for biologics, including biosimilars and innovative therapeutics. Comparable to GC Biopharma as a major Korean-based biopharmaceutical company with global manufacturing and CDMO capabilities, though Samsung Biologics is significantly larger and more focused on contract manufacturing.
- Celltrion: Korean biopharmaceutical company specializing in biosimilars and innovative biologics with global commercial reach. Comparable to GC Biopharma as a major Korean biopharma with similar product portfolio (IVIG, vaccines) and international expansion ambitions across the same regulatory markets (US, EU, Japan).
- WuXi Biologics: Global biologics CDMO providing contract development and manufacturing services for monoclonal antibodies and biologics. Comparable to GC Cell's CDMO business given similar outsourced manufacturing service offering for biologics and cell therapies globally.
- Daewoong Pharmaceutical: Korean pharmaceutical company with biopharmaceutical manufacturing, OTC consumer products, and international operations. Comparable to GC Holdings as a diversified Korean pharma with overlapping business mix including prescription drugs, biologics, and consumer health.
- Yuhan Corporation: Korean pharmaceutical company with diversified portfolio spanning prescription drugs, OTC, consumer health, and international markets. Comparable to GC Holdings as a diversified Korean healthcare conglomerate with both pharmaceutical manufacturing and consumer health divisions.
- SK Bioscience: Korean vaccine developer and manufacturer with WHO PQ-certified products for global public procurement. Directly comparable to GC Biopharma's vaccine business given similar product mix (varicella, influenza, COVID-19), shared global public health customers (WHO, UNICEF), and overlapping pipeline focus.
- Hanmi Pharmaceutical: Korean pharmaceutical company with focus on innovative therapeutics including rare disease drugs and biologics. Directly comparable as a Korean rare disease player; notably, Hanmi is also a current co-development partner with GC on the Fabry disease treatment (GC1134A/HM15421).
Broad incumbents
- Takeda Pharmaceutical: Global pharmaceutical company with major rare disease and plasma-derived therapeutics franchises (post-Shire acquisition). Comparable to GC Biopharma as a rare disease and immunoglobulin player in the same global markets, but operating at substantially larger scale.
- CSL Behring: Global leader in plasma-derived therapeutics and rare disease treatments, and the dominant player in IVIG/SCIG markets. Comparable to GC Biopharma's plasma derivatives and IVIG (Alyglo) franchise, but operating at significantly greater scale globally and competing directly in the US immunoglobulin market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks7 records
Key highlights8 records
Customer concentration
Green Cross Corporation social profiles
Digital presenceGreen Cross Corporation compliance and trust
Trust signalCompliance6 records
Green Cross Corporation financial estimates
Financial estimateRevenue estimate
Valuation estimate
Green Cross Corporation leadership team
Management profileNumber of profiles
Profiles6 records
Green Cross Corporation subsidiaries and ownership
Company hierarchySubsidiaries25 records
Green Cross Corporation funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Green Cross Corporation M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Green Cross Corporation
What does Green Cross Corporation do?
Green Cross Corporation (GC Holdings) is a Korean healthcare conglomerate operating through 40 affiliates (25 domestic, 15 overseas) that develops, manufactures, and commercializes plasma derivatives (IVIG, albumin), vaccines (varicella, influenza, hemorrhagic fever), rare disease treatments (Hunter syndrome, hemophilia, Fabry disease), and innovative therapeutics including mRNA-LNP vaccines, bispecific ADCs, and in vivo CAR-T cell therapies. The group also provides in vitro diagnostics, clinical trial lab services, consumer health functional foods, digital healthcare platforms, and cell therapy CDMO services through dedicated subsidiaries.
Is Green Cross Corporation a public or private company?
Green Cross Corporation is a public company. It is classified as public and is currently operating.
When was Green Cross Corporation founded?
Green Cross Corporation was founded in 1969. It employs 1,001 to 5,000 people.
Where is Green Cross Corporation based?
Green Cross Corporation is headquartered in Giheung, South Korea, in the Asia region.
How does Green Cross Corporation make money?
Six revenue lines are on record. Plasma Derivatives (Blood Products) is the primary driver. The others are vaccines, rare Disease Treatments, cell and Gene Therapies, in Vitro Diagnostics and Medical Devices and consumer Health Products.
Who are Green Cross Corporation's main competitors?
Direct peers on record are Iovance Biotherapeutics, Samsung Biologics, Celltrion, WuXi Biologics, Daewoong Pharmaceutical, Yuhan Corporation, SK Bioscience and Hanmi Pharmaceutical. Broad incumbents are Takeda Pharmaceutical and CSL Behring.
Does Green Cross Corporation have an API?
No public API is recorded for Green Cross Corporation.
What industry is Green Cross Corporation in?
Green Cross Corporation's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAGABAD, Cell Therapy CDMO, with a secondary code of CRAFACAC, Health & Wellness (Vitamins, Supplements, OTC) DTC. Its NAICS code is 325412 and its SIC code is 2834.